FTC Conditions Aurobindo's $250M Lannett Buyout on Generic Drug Divestitures

The Federal Trade Commission moved June 18 to safeguard American patients from potential price increases tied to Aurobindo Pharma's $250 million acquisition of generic-drug maker Lannett Company. Rather than blocking the transaction outright, the agency issued a proposed consent order that conditionally clears the merger—provided Aurobindo divests four overlapping generic products. Under the agreement, Aurobindo must sell mycophenolate mofetil oral suspension (an immunosuppressant), niacin extended-release tablets (cholesterol), pilocarpine tablets, and rabeprazole sodium delayed-release tablets (gastrointestinal) to Quagen Pharmaceuticals LLC before the deal can close. The FTC alleged that combining the two manufacturers would eliminate head-to-head competition in these four markets, shrinking the number of independent significant competitors and increasing the risk that Aurobindo could unilaterally exercise market power. In some markets, the FTC warned, remaining rivals could engage in coordinated pricing behavior—each scenario threatening to raise the cost of these generics. To ensure the remedy holds, the consent order requires Aurobindo and Lannett to provide transition services so Quagen can operate the divested assets immediately, and the companies will be overseen by a monitor to enforce compliance. The public has 30 days to comment before the FTC finalizes the order. The action reflects continued aggressive antitrust enforcement in the pharmaceutical sector, where regulators have repeatedly used targeted divestitures to preserve competition in generic-drug markets that directly affect consumer out-of-pocket costs. Generic drugs account for roughly 90% of prescriptions dispensed in the United States, making even narrow overlaps a focus of scrutiny. For Aurobindo Pharma—one of India's largest generic manufacturers and a major supplier to the U.S. market—the structured remedy allows the strategically important Lannett acquisition to proceed with limited disruption, since the divested products represent a small slice of the combined portfolio. Lannett, which restructured through bankruptcy in 2023 and is no longer publicly traded, becomes part of Aurobindo's expanding U.S. footprint. The outcome is broadly consistent with how the market and analysts expected the review to resolve: a manageable, surgical divestiture rather than a deal-ending challenge. Investors in Aurobindo (AUROPHARMA on the NSE/BSE) gain clarity that the transaction can advance, while regulators secure a commitment intended to keep prices for the affected generics competitive.